We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Lexicon (LXRX) Starts Dosing in Post-Herpetic Neuralgia Study
Read MoreHide Full Article
Lexicon Pharmaceuticals, Inc. (LXRX - Free Report) announced that it commenced patient dosing in a phase II randomized, placebo-controlled, multi-center clinical study RELIEF-PHN 1, which is currently evaluating its pipeline candidate LX9211.
The study is evaluating the efficacy, safety and pharmacokinetics of LX9211 for the treatment of post-herpetic neuralgia, the most common complication of shingles. LX9211 is a potent oral small molecule inhibitor of adaptor associated kinase 1 (AAK1).
The study is designed to enroll approximately 74 patients at approximately 30 clinical sites. The primary efficacy endpoint is the change in Average Daily Pain Score (ADPS) from baseline (day 1) to week 6, based on the 11-point numerical rating scale (NRS).
Lexicon intends to complete this study and its other proof-of-concept study of LX9211 for diabetic peripheral neuropathic pain by the end of 2021.
We note that Lexicon identified LX9211 and another development candidate in a neuroscience drug discovery alliance with Bristol-Myers Squibb (BMY - Free Report) from which it holds exclusive development and commercialization rights.
The candidate also received a Fast rack designation from the FDA for addressing diabetic peripheral neuropathic pain.
Shares of Lexicon have declined 13.2% in the past year against the industry’s growth of 7.4%.
Meanwhile, Lexicon is also developing Zynquista (sotagliflozin), an orally-delivered small molecule drug candidate, as a treatment of type 1 diabetes. The FDA issued a complete response letter to the company’s application for a regulatory approval to market sotagliflozin for type 1 diabetes in the United States. Nevertheless, the drug is already approved in the European Union for use as an adjunct to insulin therapy for improving glycemic control in adults with type 1 diabetes and a body mass index greater than or equal to 27 kg/m2, who could not achieve adequate glycemic control despite undergoing optimal insulin therapy. However, the medicine is yet to be commercially launched. The company earlier had a license agreement with Sanofi (SNY - Free Report) for this product.
Halozyme’s earnings estimates have grown 22 cents per share for 2021 in the past 60 days.
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
Image: Bigstock
Lexicon (LXRX) Starts Dosing in Post-Herpetic Neuralgia Study
Lexicon Pharmaceuticals, Inc. (LXRX - Free Report) announced that it commenced patient dosing in a phase II randomized, placebo-controlled, multi-center clinical study RELIEF-PHN 1, which is currently evaluating its pipeline candidate LX9211.
The study is evaluating the efficacy, safety and pharmacokinetics of LX9211 for the treatment of post-herpetic neuralgia, the most common complication of shingles. LX9211 is a potent oral small molecule inhibitor of adaptor associated kinase 1 (AAK1).
The study is designed to enroll approximately 74 patients at approximately 30 clinical sites. The primary efficacy endpoint is the change in Average Daily Pain Score (ADPS) from baseline (day 1) to week 6, based on the 11-point numerical rating scale (NRS).
Lexicon intends to complete this study and its other proof-of-concept study of LX9211 for diabetic peripheral neuropathic pain by the end of 2021.
We note that Lexicon identified LX9211 and another development candidate in a neuroscience drug discovery alliance with Bristol-Myers Squibb (BMY - Free Report) from which it holds exclusive development and commercialization rights.
The candidate also received a Fast rack designation from the FDA for addressing diabetic peripheral neuropathic pain.
Shares of Lexicon have declined 13.2% in the past year against the industry’s growth of 7.4%.
Zacks Rank & Another Stock to Consider
Lexicon currently carries a Zacks Rank #2 (Buy). Another top-ranked player in the biotech space is Halozyme Therapeutics, Inc. (HALO - Free Report) , which presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Halozyme’s earnings estimates have grown 22 cents per share for 2021 in the past 60 days.
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
See the 5 high-tech stocks now>>